Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EDIT-202
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Editas Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the terms of the agreement, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors and an additional iNK program under development and certain related manufa...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 19, 2023
Lead Product(s) : EDIT-202
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Editas Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Kite Pharma
Deal Size : $2,300.0 million
Deal Type : Partnership
Details : The collaboration will leverage Shoreline’s deep expertise in iPSC differentiation and genetic reprogramming in combination with Kite’s extensive cell therapy expertise to develop novel allogeneic candidates for a range of hematologic malignancies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Kite Pharma
Deal Size : $2,300.0 million
Deal Type : Partnership